Health Care · Pharmaceutical Preparations · OTC · CIK 1347242 · FYE Dec 31 · Prices AT CLOSE 2026-08-19 (USD) Last $0.00 · Day +0.00% · Mkt cap $1,386 · 1Y −88.8% · Off 52W high −89.7% · Vol (1Y) 357.3% Price2023-08-21 → 2026-08-19 LIPO close: $0.10 on 2023-08-21 to $0.00 on 2026-08-19. Split-adj closes · 240 of 916 · price returnⓘ At a glance | Short interest0.1% of sh out | | Days to cover1.0d | | Next report (est.)2026-11-17 |
SI 2026-07-31ⓘ Key fundamentalsFY 2024 | Sales (TTM)$470,163 | | Earnings (TTM)-$5.3M | | ROE−198.1% | | Net margin−935.2% | | Sales growth 3Y27.4% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD−63.3% | | 1Y−88.8% | | 3Y−99.6% | | Since incept. (ann.)−82.3% |
Total return · from 2022-12-20ⓘ Risk | Ann. volatility (1Y)357.3% | | Ann. volatility (3Y)242.5% | | Sharpe (1Y)0.86 | | Sharpe (3Y)0.25 | | Max drawdown (1Y)−96.9% | | Max drawdown (3Y)−99.9% | | Beta (3Y vs SPY)1.97 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 No 13F holders on file for LIPO. Latest reported quarterslast report 2025-11-14 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2025-09-30 | 2025-11-14 | −$0.28 | — | — | — | | 2025-06-30 | 2025-08-14 | −$0.31 | — | $86,727 | −36.4% | | 2025-03-31 | 2025-05-14 | −$0.64 | — | $129,390 | −11.3% | | 2024-12-31 | 2025-03-28 | — | — | $173,666 | +43.7% |
As-reported XBRL · next 2026-11-17 est.ⓘ Segment mixFY2024 (ended Dec 2024) Grantrevenues 100% product & service · TAGGED revenueⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
| 
